---
title: "What will the FDA's decision be on Zidesamtinib by Nuvalent in 2026?"
canonical_url: https://betcrypto.now/events/what-will-the-fdas-decision-be-on-zidesamtinib-by-nuvalent-in-2026
status: settled
trading_closes_at: 2026-07-22T19:07:31+00:00
settled_at: 2026-07-22T19:07:31+00:00
total_volume_usd: 1509.91
venues: ["Kalshi"]
categories: ["Markets"]
prices_as_of: 2026-10-12T13:38:49+00:00
publisher: BetCrypto
data_api: https://betcrypto.now/api/v1/events/what-will-the-fdas-decision-be-on-zidesamtinib-by-nuvalent-in-2026
---

# What will the FDA's decision be on Zidesamtinib by Nuvalent in 2026?

Settled · $1,510 traded · listed on Kalshi

## Result

**Yes** won. Settled 2026-07-22.

## About

If the FDA's decision on Zidesamtinib by Nuvalent in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. 

Zidesamtinib (also known by its development code NVL-520) is an experimental cancer medicine made by Nuvalent Inc. that is designed to fight a specific type of lung cancer driven by a faulty molecular switch called ROS1. Think of ROS1 as a car's accelerator pedal stuck in the "floored" position — it keeps cancer cells growing uncontrollably — and zidesamtinib acts like a clamp that holds the pedal back, slowing or stopping that runaway growth. It is a small-molecule drug, meaning it is taken as a pill and can travel throughout the body, including into the brain, where ROS1-driven lung cancers commonly spread.

_From Kalshi's listing._

## Open on a venue

- [Kalshi](https://betcrypto.now/go/e/2091?via=md)

---

Probability is the cross-venue consensus (book midpoints, 0–100%). Venue columns are what buying costs there (the ask). Prices move constantly; re-check at the canonical URL or https://betcrypto.now/api/v1/events/what-will-the-fdas-decision-be-on-zidesamtinib-by-nuvalent-in-2026.

BetCrypto is an odds-comparison and information service. It accepts no wagers and gives no betting or financial advice; prediction-market availability depends on where you live.